Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol CYP2C9 contributors: mct - updated : 17-11-2021
HGNC name cytochrome P450, family 2, subfamily C, polypeptide 9
HGNC id 2623
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • N-terminal ER-transmembrane domain
  • a large, cytoplasmic catalytic domain
  • conjugated HemoP
    mono polymer monomer
    HOMOLOGY
    Homologene
    FAMILY
  • cytochrome P450 subfamily IIC
  • multigenic cytochrome P450 superfamily of mixed-function monooxygenases
  • CATEGORY enzyme , transport
    SUBCELLULAR LOCALIZATION     intracellular
    intracellular,cytoplasm,organelle,membrane
    intracellular,cytoplasm,organelle,endoplasmic reticulum ,rough,smooth
    intracellular,cytoplasm,cytosolic,microsome
    basic FUNCTION
  • involved in an NADPH-dependent electron transport pathway and oxidizing a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics
  • hydroxylating many xenobiotics inducing phenytoin, S-warfarin, and tolbutamide
  • CYP2C9 and CYP2C19 are important drug-metabolizing enzymes and together metabolize approximately 20 p100 of therapeutically used drugs
  • cytochrome P450 enzyme responsible for metabolizing up to 15 p100 of small molecule drugs
  • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS electron transport , detoxification
    PATHWAY
    metabolism drug
    signaling
    oxidative metabolism
    a component
    INTERACTION
    DNA
    RNA
    small molecule cofactor, nucleotide,
    NADPH, heme
    protein flavoprotein P450 oxidoreductase (POR)
    cell & other
    REGULATION
    induced by rifampin
    ASSOCIATED DISORDERS
    corresponding disease(s)
    related resource Human Cytochrome P450 (CYP) Allele Nomenclature Committee
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --low  
    in multiple cohorts of human esophageal squamous cell carcinoma (ESCC)
    Susceptibility
  • to adverse drug reactions/toxicities when drugs extensively metabolized by CYP2C9
  • to warfarin resistance
  • to variation of the metabolism of warfarin and other drugs
  • Variant & Polymorphism SNP , other
  • variability interindividual and ethnic
  • increasing the warfarin resistance
  • CYP2C9 variants have significantly decreased function and have the potential to impact the metabolism of warfarin and other drugs
  • Candidate gene
    Marker
    Therapy target
    SystemTypeDisorderPubmed
    cancerdigestiveoesophagus
    Overexpression of CYP2C9 reduced the invasion and migration of esophageal squamous cell carcinoma (ESCC) cells
    ANIMAL & CELL MODELS